Table 3.
Allele and genotype frequencies in PD patients and controls by percentage of Native American ancestry.
| ID Marker | Group 1 (32–52%) | Group 2 (52.1–58.5%) | Group 3 (56.6–65%) | Group 4 (≥66%) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MAa n (freq) | Genotype | OR [95% CI] | MAa n (freq) | Genotype | OR [95% CI] | MAa n (freq) | Genotype | OR [95% CI] | MAa n (freq) | Genotype | OR [95% CI] | |||||||||
| rs1801133 | CC | CT | TT | 2.02 | CC | CT | TT | 1.54 | CC | CT | TT | 1.54 | CC | CT | TT | 1.11 | ||||
| PD |
31 (0.53) |
9 (0.31) |
9 (0.31) |
11 (0.38) |
[1.02–4.03] |
34 (0.57) |
5 (0.17) |
16 (0.53) |
9 (0.30) |
[0.77–2.26] |
40 (0.62) |
5 (0.17) |
14 (0.44) |
13 (0.40) |
[0.77–2.76] |
32 (0.60) |
4 (0.15) |
14 (0.52) |
9 (0.33) |
[1.56–2.11] |
| CNT |
38 (0.39) |
17 (0.35) |
26 (0.53) |
6 (0.12) |
40 (0.42) |
16 (0.33) |
24 (0.50) |
8 (0.17) |
48 (0.52) |
12 (0.26) |
20 (0.44) |
14 (0.30) |
57 (0.57) |
10 (0.20) |
23 (0.43) |
17 (0.34) |
||||
| p = 0.09 | p = 0.02 | p = 0.04 | p = 0.07 | p = 0.2 | p = 0.2 | p = 0.3 | p = 0.5 | p = 0.24 | p = 0.87 | p = 0.9 | p = 0.75 | |||||||||
| rs1491942 | CC | CG | GG | 1.0 | CC | CG | GG | 1.5 | CC | CG | GG | 2.26 | CC | CG | GG | 2.94 | ||||
| PD |
38 (0.66) |
4 (0.14) |
12 (0.41) |
13 (0.45) |
[0.50–1.99] |
37 (0.62) |
5 (0.17) |
27 (0.56) |
12 (0.40) |
[0.75–3.04] |
44 (0.68) |
2 (0.07) |
16 (0.50) |
14 (0.43) |
[1.04–4.91] |
36 (0.66) |
3 (0.12) |
12 (0.44) |
12 (0.44) |
[1.38–6.23] |
| CNT |
64 (0.65) |
6 (0.12) |
22 (0.45) |
21 (0.43) |
51 (0.53) |
9 (0.19) |
13 (0.43) |
1 (0.38) |
50 (0.54) |
9 (0.19) |
24 (0.52) |
13 (0.28) |
40 (0.40) |
20 (0.40) |
20 (0.40) |
10 (0.20) |
||||
| p = 0.99 | p = 0.9 | p = 0.99 | p = 0.32 | p = 0.4 | p = 0.2 | p = 0.1 | p = 0.1 | p = 0.04 | p = 0.002 | p = 0.01 | p = 0.01 | |||||||||
Group 1 n = 78 subjects; group 2 n = 78 subjects; group 3 n = 78 subjects; group 4 n = 77 subjects.
PD Parkinson disease group, CNT control group.
aMA minor allele, B additive model.